AU2019337338A1 - Musk inhibition - Google Patents

Musk inhibition Download PDF

Info

Publication number
AU2019337338A1
AU2019337338A1 AU2019337338A AU2019337338A AU2019337338A1 AU 2019337338 A1 AU2019337338 A1 AU 2019337338A1 AU 2019337338 A AU2019337338 A AU 2019337338A AU 2019337338 A AU2019337338 A AU 2019337338A AU 2019337338 A1 AU2019337338 A1 AU 2019337338A1
Authority
AU
Australia
Prior art keywords
seq
specific
antibody
binding
musk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019337338A
Other languages
English (en)
Inventor
Martina Gerardina Maria HUIJBERS
Jakob Jan PLOMP
Silvère Maria VAN DER MAAREL
Johannes Justus Gerard Maria VERSCHUUREN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2021589A external-priority patent/NL2021589B1/en
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Publication of AU2019337338A1 publication Critical patent/AU2019337338A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019337338A 2018-09-10 2019-09-05 Musk inhibition Abandoned AU2019337338A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2021589A NL2021589B1 (en) 2018-09-10 2018-09-10 MuSK inhibition
NL2021589 2018-09-10
NL2023119 2019-05-13
NL2023119 2019-05-13
PCT/NL2019/050576 WO2020055240A1 (en) 2018-09-10 2019-09-05 Musk inhibition

Publications (1)

Publication Number Publication Date
AU2019337338A1 true AU2019337338A1 (en) 2021-04-08

Family

ID=68138766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019337338A Abandoned AU2019337338A1 (en) 2018-09-10 2019-09-05 Musk inhibition

Country Status (8)

Country Link
US (1) US20220002438A1 (https=)
EP (1) EP3850014A1 (https=)
JP (2) JP2022500387A (https=)
CN (1) CN113614112A (https=)
AU (1) AU2019337338A1 (https=)
CA (1) CA3112288A1 (https=)
IL (1) IL281409A (https=)
WO (1) WO2020055240A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114487448B (zh) * 2022-01-21 2022-10-18 天津天海新域生物科技有限公司 用于检测重症肌无力相关抗体的组合物、试剂盒及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US7759314B2 (en) * 2001-08-15 2010-07-20 Brown University Treatment of muscular dystrophies and related disorders
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7807378B2 (en) * 2005-12-29 2010-10-05 Industrial Technology Research Institute (Itri) Method of diagnosing myasthenia gravis and kits therefor
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
JP2011207769A (ja) * 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
JP2014520148A (ja) * 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
WO2013074636A1 (en) * 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
WO2015039015A2 (en) * 2013-09-13 2015-03-19 New York University Methods for treating muscle specific receptor kinase myasthenia gravis
JP7023840B2 (ja) * 2015-10-07 2022-02-22 メモリアル スローン ケタリング キャンサー センター 神経筋接合活性のモジュレーターを同定するｉｎ ｖｉｔｒｏの方法

Also Published As

Publication number Publication date
CA3112288A1 (en) 2020-03-19
JP2025016653A (ja) 2025-02-04
EP3850014A1 (en) 2021-07-21
US20220002438A1 (en) 2022-01-06
JP2022500387A (ja) 2022-01-04
WO2020055240A1 (en) 2020-03-19
CN113614112A (zh) 2021-11-05
IL281409A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
EP3728315A1 (en) Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
RS52439B (sr) Humana antitela prema humanom delti sličnom ligandu 4
KR20240060864A (ko) 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
JP2021521881A (ja) 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用
WO2021207242A2 (en) Anti-mesothelin antigen-binding molecules and uses thereof
CN108350079A (zh) 用于治疗神经学和其它病症的结合激动剂
TW201945400A (zh) 抗TrkA抗體
KR20260013489A (ko) TrkA 항체 및 이의 용도
US20250084173A1 (en) TrkA ANTIBODY AND APPLICATION THEREOF
JP2025016653A (ja) Ｍｕｓｋ阻害
CN111295395B (zh) 抗体和使用方法
US20240043562A1 (en) Musk activation
NL2021591B1 (en) MuSK activation
NL2021589B1 (en) MuSK inhibition
WO2023030511A1 (en) Bi-functional fusion protein and uses thereof
KR20240026959A (ko) 항-ｔｒｅｍ-1 항체
CN104781280A (zh) 抗前动力蛋白受体(prokr)抗体及其使用
CN111234021B (zh) 一种抗ccr5抗体及其在治疗肿瘤中的应用
KR20240015800A (ko) 뇌신경계 질환을 치료하기 위하여 혈관뇌장벽을 통과할 수 있는 이중특이적 항체와 결합체
KR20230124910A (ko) 염증성 피부 상태 치료 방법
JP2026507922A (ja) 制御性ｔ細胞表面抗原のエピトープおよびこれに特異的に結合する抗体
TW202506724A (zh) 抗igf1r抗體及其用途
KR20240015200A (ko) 뇌신경계 질환 치료하기 위한 병용투여용 항체 및 이를 포함하는 약학조성물

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application